Goldman Sachs Group »

Sab Biotherapeutics shares owned by Goldman Sachs Group

Quarter-by-quarter ownership of Sab Biotherapeutics (SABS) shares owned by Goldman Sachs Group from 13F filings

Historical chart of Goldman Sachs Group investment in Sab Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Sab Biotherapeutics held by Goldman Sachs Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sab Biotherapeutics by Goldman Sachs Group

Quarter filed Position value Share count Share price at filing
2025-09-30 $23k 11k 2.01

More positions owned by Goldman Sachs Group

Nvidia Corporation CMN (NVDA)
Spdr S&p 500 Etf Tr CMN (SPY)
Microsoft Corp CMN (MSFT)
Apple CMN (AAPL)
Invesco Qqq Tr CMN Put Option (QQQ)
Tesla CMN (TSLA)
Amazon CMN (AMZN)
Meta Platforms CMN (META)
Alphabet CMN (GOOGL)
Broadcom CMN (AVGO)
Ishares Tr CMN (IVV)
Ishares Tr CMN Put Option (IWM)
Vanguard Index Fds CMN (VOO)
Ishares Tr CMN Put Option (HYG)
Jpmorgan Chase & Co. CMN (JPM)

View all positions for Goldman Sachs Group

Top funds holding Sab Biotherapeutics

Vivo Capital
RA Capital Management
Commodore Capital
Woodline Partners
Sessa Capital IM
BVF
Sphera Funds Management
Vanguard Group
HB Wealth Management
AWM Investment Company
Geode Capital Management
Renaissance Technologies
Pathstone Holdings
Virtu Financial
Kovitz Investment Group Partners

View all funds holding Sab Biotherapeutics